RECURRENT FALLOPIAN TUBE CARCINOMA
Clinical trials for RECURRENT FALLOPIAN TUBE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT FALLOPIAN TUBE CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT FALLOPIAN TUBE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested in battle against tough ovarian cancer
Disease control CompletedThis study tested two different ways of giving immunotherapy drugs (durvalumab and tremelimumab) to women with recurrent ovarian, fallopian tube, or primary peritoneal cancer that had stopped responding to standard platinum-based chemotherapy. The goal was to see if giving the dr…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Precision radiation zaps recurrent cancers in early safety trial
Disease control CompletedThis early-stage study tested a specialized, high-precision form of radiation therapy for women whose ovarian or uterine cancer has returned in a few specific spots. The main goal was to find the highest dose that is safe and causes manageable side effects. Researchers also wante…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Doctors test personalized cancer vaccine in small ovarian cancer study
Disease control CompletedThis small, early-stage study tested a personalized vaccine for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. The vaccine was made from a patient's own white blood cells, trained to target a protein found on cancer cells. The main goals were to che…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New hope for Tough-to-Treat ovarian cancer?
Disease control CompletedThis study tested whether adding a new oral drug called relacorilant to standard chemotherapy (nab-paclitaxel) could better control cancer growth in women with recurrent ovarian, fallopian tube, or primary peritoneal cancer that had stopped responding to platinum-based drugs. It …
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC